United States to India: Herbal Import Trade Route

The United States to India Herbal corridor is one of India's established pharmaceutical import routes from United States, with 1 shipments documented worth a combined $3.6K USD. The route is dominated by NOVOZYMES A/S, which alone accounts for roughly 100% of all import value, reflecting the consolidated nature of United States's herbal export sector.

Across 1 active United States suppliers, the average shipment value stands at $3.6K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 85% of all shipments, consistent with herbal's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 27 days port-to-port. The route has recorded an annual growth rate of 28.7%, placing it at rank #18 among India's top herbal import origins globally.

On the Indian buyer side, key Indian importers include NOVOZYMES SOUTH ASIA PRIVATE LIMITED. NOVOZYMES SOUTH ASIA PRIVATE LIMITED is the single largest Indian importer with 1 shipments valued at $3.6K USD.

India's herbal imports from United States are driven primarily by a handful of large-scale United States manufacturers. NOVOZYMES A/S with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 1 active exporters signals a competitive but concentrated market — Indian buyers benefit from United States supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — NOVOZYMES A/S — together account for 100% of total trade value on this route. The average shipment value of $3.6K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

On the buying side, NOVOZYMES SOUTH ASIA PRIVATE LIMITED is the largest importer with 1 shipments worth $3.6K USD — representing 100% of all herbal imports from United States on this route.